STOCK TITAN
  1. Home
  2. Sec-filings
  3. TSHA
  4. [Form 4] Taysha Gene Therapies, Inc. Insider Trading Activity

Sukumar trades TSHA stock, options and RSUs in Form 4 filing details

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Taysha Gene Therapies president and head of R&D Nagendran Sukumar reported multiple stock transactions on January 12, 2026. He exercised options for 111,324 shares of common stock at an exercise price of $0.6989 per share and 88,676 shares at $1.71 per share, then sold 200,000 shares of common stock at a weighted average price of $4.71 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025.

After these moves, he directly held 1,006,439 shares of common stock before receiving an additional 427,000 restricted stock units, which increased his reported common stock holdings to 1,433,439 shares. He also received a new employee stock option for 274,000 shares at an exercise price of $4.86 per share, vesting over time starting January 12, 2027.

Positive

  • None.

Negative

  • None.
Insider Nagendran Sukumar
Role President and Head of R&D
Sold 200,000 shs ($942K)
Approx. gross sale proceeds $942K
Approx. exercise cost $229K
Approx. pre-tax spread $713K
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 111,324 $0.00 $0.00
Exercise Employee Stock Option (right to buy) 88,676 $0.00 $0.00
Grant/Award Employee Stock Option (right to buy) 274,000 $0.00 $0.00
Exercise Common Stock 111,324 $0.6989 $78K
Exercise Common Stock 88,676 $1.71 $152K
Sale Common Stock 200,000 $4.71 $942K
Grant/Award Common Stock 427,000 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 860,300 shares (Direct); Common Stock — 1,433,439 shares (Direct)
Footnotes (6)
  1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
  4. F4. The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
  5. F5. 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
  6. F6. 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

Who is the insider trading TSHA stock in this Form 4 filing?

The reporting person is Nagendran Sukumar, who serves as a director and as President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA).

How many TSHA shares did Nagendran Sukumar sell in this Form 4?

On January 12, 2026, Nagendran Sukumar sold 200,000 shares of Taysha Gene Therapies common stock at a weighted average price of $4.71 per share, with individual sale prices ranging from $4.565 to $4.92.

Were the TSHA stock sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the stock sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2025.

What option exercises did Nagendran Sukumar report for TSHA on January 12, 2026?

He exercised employee stock options covering 111,324 shares of common stock at an exercise price of $0.6989 per share and 88,676 shares at $1.71 per share, both on January 12, 2026.

What new equity awards did Nagendran Sukumar receive from TSHA in this Form 4?

The filing reports a new RSU award of 427,000 units, vesting in four equal annual installments beginning on January 12, 2027, and a new employee stock option for 274,000 shares at an exercise price of $4.86 per share, with 25% vesting on January 12, 2027 and the remainder vesting in 36 equal monthly installments.

How many TSHA common shares did Nagendran Sukumar hold after the reported transactions?

Following the reported transactions on January 12, 2026, he directly held 1,433,439 shares of Taysha Gene Therapies common stock.

How many TSHA options does Nagendran Sukumar hold after these transactions?

After the option exercises and the new grant, he held 111,359 employee stock options at an exercise price of $0.6989, 474,941 options at $1.71, and a newly granted 274,000 options at $4.86 per share.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nagendran Sukumar
(Last) (First) (Middle)
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
(Street)
DALLAS TX 75247
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and Head of R&D
3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/12/2026 M 111,324 A $0.6989 1,117,763 D
Common Stock 01/12/2026 M 88,676 A $1.71 1,206,439 D
Common Stock 01/12/2026 S(1) 200,000 D $4.71(2) 1,006,439 D
Common Stock 01/12/2026 A 427,000(3) A $0 1,433,439 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $0.6989 01/12/2026 M 111,324 (4) 12/14/2033 Common Stock 111,324 $0 111,359 D
Employee Stock Option (right to buy) $1.71 01/12/2026 M 88,676 (5) 01/02/2034 Common Stock 88,676 $0 474,941 D
Employee Stock Option (right to buy) $4.86 01/12/2026 A 274,000 (6) 01/12/2036 Common Stock 274,000 $0 274,000 D
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
4. The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
5. 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
6. 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact 01/14/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR